<DOC>
	<DOCNO>NCT00478569</DOCNO>
	<brief_summary>The primary objective : 1 ) describe adherence ( main factor influence adherence ) PTH ( 1-84 ) treatment prescribe normal clinical setting . The secondary objective : 1. describe demographic clinical characteristic patient normal clinical setting start treatment regimen PTH ( 1-84 ) 2. describe ( use available data ) long term treatment effectiveness 24 month follow initiation PTH ( 1-84 ) treatment normal clinical set 3. monitor safety 24 month follow initiation PTH ( 1-84 ) treatment patient normal clinical setting .</brief_summary>
	<brief_title>Adherence PTH ( 1-84 ) Treatment ( FP-002-IM )</brief_title>
	<detailed_description />
	<mesh_term>Hormones</mesh_term>
	<criteria>According current Summary Product Characteristics ( SmPC ) PTH ( 184 ) treatment initiate within one month precede enrolment The patient 's write informed consent direct access data processing must obtain . According current SmPC The patient participate clinical trial PTH ( trial allow ) .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>